ASKA Pharmaceutical Holdings CO., Ltd. (4886) Stock Price

Asuka Pharmaceutical Holdings was established on April 1, 2021, as the parent company of Asuka Pharmaceutical Co., Ltd., and operates as a holding company managing the operations of its group companies. The Asuka Pharmaceutical group consists of Asuka Pharmaceutical Holdings as the core entity, along with 5 subsidiaries and 4 affiliated companies.

The company's business is divided into four segments. First, the pharmaceutical business primarily manufactures and sells prescription pharmaceuticals. Through the provision of pharmaceuticals to medical institutions and patients, the company contributes to the maintenance and improvement of health.

Second, the animal health business manufactures and sells veterinary pharmaceuticals and feed additives. This segment supports the health management of livestock and pets, and contributes to the efficiency of the livestock industry.

Third, the overseas business primarily manufactures and sells prescription pharmaceuticals in overseas markets. Through this, the company meets global healthcare needs and strengthens its presence in international markets.

Finally, the other business segment operates clinical laboratory testing and medical device businesses. This supports diagnosis and treatment in medical settings and contributes to improving the quality of healthcare.

Asuka Pharmaceutical Holdings operates under the mission of "contributing to people's health and tomorrow's society through advanced drug discovery." The company's core business is prescription pharmaceuticals, complemented by animal health and diagnostic testing operations. Since fiscal 2021, the company has adopted a holding company structure to enable faster decision-making and strengthen governance.

The company has established a medium-term management plan from 2021 to 2026, targeting net sales of 70 billion yen, an operating profit margin of 8%, and ROE of 8% by fiscal 2025. Through these targets, the company aims to achieve sustainable growth, address social challenges, and contribute to SDG achievement.

As part of its growth strategy, the company is strengthening the development and sales of obstetric and gynecological products to improve women's quality of life. The company also promotes new drug creation through open innovation and is expanding overseas operations primarily in Asia to strengthen its global presence.

Additionally, the company is establishing a business model for minimally invasive diagnostic methods and developing products that support companion animal health. The company is pursuing operational efficiency and cost reduction through IT utilization while strengthening its financial foundation.

In human resources management, the company has introduced a new personnel system to build an organizational structure that accommodates diverse career aspirations. Through planned training and development programs, the company is expanding employee capabilities to support the realization of its growth strategy.

Specifically, in the pharmaceutical business, the company is advancing new drug development and expanding markets both domestically and internationally. The company is particularly focused on strengthening its presence in the obstetric and gynecological field by enhancing information provision activities, thereby continuing to provide high-quality medical care.

In overseas operations, the company is strengthening its business expansion in Southeast Asia, particularly Vietnam. The company is advancing collaboration with local pharmaceutical companies to expand its regional presence and enhance competitiveness in international markets.

Toward realizing a total healthcare company, the company is strengthening collaboration with other companies. Through partnerships with startups focused on addressing women's health issues, the company aims to create new value and establish itself as a company that contributes to society.